Supernus Pharmaceuticals, Inc. - Common Stock (SUPN)
Frequently Asked Questions About Supernus Pharmaceuticals, Inc. - Common Stock (SUPN)
Does Supernus Pharmaceuticals offer patient assistance programs?
Yes, Supernus Pharmaceuticals offers patient assistance programs aimed at helping eligible patients access their medications. These programs are designed to provide financial support and ensure that patients can maintain their treatment regimens without undue burden.
How can investors learn more about Supernus Pharmaceuticals?
Investors can learn more about Supernus Pharmaceuticals by visiting the company’s official website, which provides comprehensive information including investor presentations, financial reports, press releases, and recent updates on product developments and corporate strategy.
How does Supernus Pharmaceuticals approach research and development?
Supernus Pharmaceuticals employs a strategically focused approach to research and development, leveraging its expertise in formulation technologies and clinical trial design. The company enhances its pipeline through both internal development and collaborations to foster innovation and expedite the availability of new therapies.
How does Supernus Pharmaceuticals ensure product safety and efficacy?
Supernus Pharmaceuticals ensures product safety and efficacy through rigorous clinical trials, adherence to regulatory standards, and continuous pharmacovigilance practices. The company is committed to the highest quality standards in its research, development, and post-marketing activities.
Is Supernus Pharmaceuticals a publicly traded company?
Yes, Supernus Pharmaceuticals is publicly traded on the NASDAQ stock exchange under the ticker symbol SUPN. The company became publicly listed to raise capital for further development of its product portfolio and to enhance shareholder value.
What are some of Supernus Pharmaceuticals' main products?
Supernus Pharmaceuticals offers several key products in the CNS space, including Oxtellar XR (oxcarbazepine) for epilepsy and mydayis, an extended-release formulation for ADHD. These products highlight the company’s focus on innovative long-acting therapies that meet the needs of patients and healthcare providers.
What are Supernus Pharmaceuticals’ goals?
Supernus Pharmaceuticals aims to be a leader in the development of innovative treatments for central nervous system disorders. The company's goals include expanding its product pipeline, seeking new indications for existing therapies, and improving patient outcomes through effective medicines.
What are the key therapeutic areas focused on by Supernus Pharmaceuticals?
Supernus Pharmaceuticals primarily focuses on therapeutic areas related to the central nervous system, specifically epilepsy and attention-deficit/hyperactivity disorder (ADHD). These areas represent significant unmet patient needs, and Supernus is committed to developing effective treatments.
What are the key values that drive Supernus Pharmaceuticals?
The key values that drive Supernus Pharmaceuticals include integrity, innovation, patient-centeredness, and collaboration. These values guide the company's operations, decision-making processes, and interactions with stakeholders, helping to foster a positive impact on patients and the healthcare community.
What challenges does Supernus Pharmaceuticals face?
Supernus Pharmaceuticals faces several challenges, including increasing competition in the pharmaceutical industry, regulatory hurdles in drug development, and the need to continuously innovate to meet evolving patient needs. The company actively works to navigate these challenges through strategic planning and focused resource allocation.
What does Supernus Pharmaceuticals, Inc. do?
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products for the treatment of central nervous system diseases, particularly epilepsy and other disorders such as ADHD. The company's portfolio includes several approved products, and it is dedicated to advancing therapies that improve the quality of life for patients.
What is the corporate culture like at Supernus Pharmaceuticals?
The corporate culture at Supernus Pharmaceuticals is characterized by innovation, teamwork, and a strong commitment to improving patient health. The company values collaboration and encourages employees to contribute their insights and expertise to drive progress in its mission.
What is the financial performance of Supernus Pharmaceuticals?
Supernus Pharmaceuticals has exhibited strong financial performance, marked by steady revenue growth primarily from its marketed products. The company regularly reports its financial results, reflecting its ability to capitalize on market opportunities while continuing to invest in R&D for future growth.
What is the vision of Supernus Pharmaceuticals?
The vision of Supernus Pharmaceuticals is to become a leading biopharmaceutical company recognized for its innovative treatment solutions in central nervous system disorders. The company aims to enhance the lives of patients through focused research, effective medications, and robust patient support initiatives.
What recent developments has Supernus Pharmaceuticals announced?
Supernus Pharmaceuticals has recently announced several positive developments, including successful clinical trials for new product candidates and strategic partnerships aimed at enhancing its research capabilities. The company routinely updates its investors and the public on progress through press releases and financial reports.
What role do partnerships play in Supernus Pharmaceuticals' strategy?
Partnerships play a crucial role in Supernus Pharmaceuticals' strategy by facilitating access to new technologies, expanding its research capabilities, and creating synergies that enhance its development efforts. The company seeks collaborations that align with its goals and enhance its product pipeline.
When was Supernus Pharmaceuticals founded?
Supernus Pharmaceuticals was founded in 2005. Since its inception, the company has been committed to addressing unmet medical needs in the CNS disease space, and it has grown significantly through the development and commercialization of its product offerings.
Where is Supernus Pharmaceuticals headquartered?
Supernus Pharmaceuticals is headquartered in Rockville, Maryland, USA. This location provides the company with access to a vibrant biotechnology and pharmaceutical community, facilitating partnerships and collaborations that advance its research and development efforts.
Who is the CEO of Supernus Pharmaceuticals?
As of the latest available information, Jack Khattar serves as the President and Chief Executive Officer of Supernus Pharmaceuticals. He brings extensive experience in the pharmaceutical industry and has been instrumental in guiding the company’s strategic direction and growth.
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 32.78
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 3:37 pm EDT on April 3rd, 2025
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 1.74B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 53.15M shares outstanding.